Dyne Therapeutics (DYN) News Today $8.28 -1.14 (-12.10%) Closing price 04:00 PM EasternExtended Trading$8.28 0.00 (-0.06%) As of 05:39 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 Time Period Dyne Therapeutics (NASDAQ:DYN) Trading 6.1% Higher - What's Next?Dyne Therapeutics (NASDAQ:DYN) Trading 6.1% Higher - Here's What HappenedApril 4 at 12:57 PM | marketbeat.comPrudential Financial Inc. Decreases Stock Position in Dyne Therapeutics, Inc. (NASDAQ:DYN)Prudential Financial Inc. decreased its position in Dyne Therapeutics, Inc. (NASDAQ:DYN - Free Report) by 43.1% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 145,510 shares of the company's stock aftApril 3 at 3:51 AM | marketbeat.comOversold Conditions For Dyne TherapeuticsApril 3 at 3:44 AM | nasdaq.comDyne Therapeutics (NASDAQ:DYN) Hits New 52-Week Low - Time to Sell?Dyne Therapeutics (NASDAQ:DYN) Sets New 1-Year Low - Should You Sell?April 2 at 4:11 AM | marketbeat.comDyne Therapeutics (NASDAQ:DYN) Shares Gap Down - Should You Sell?Dyne Therapeutics (NASDAQ:DYN) Shares Gap Down - Time to Sell?April 1 at 1:17 PM | marketbeat.comSensei Biotherapeutics (SNSE) Gets a Buy from OppenheimerMarch 30, 2025 | markets.businessinsider.comRaymond James Financial Inc. Takes Position in Dyne Therapeutics, Inc. (NASDAQ:DYN)Raymond James Financial Inc. bought a new position in Dyne Therapeutics, Inc. (NASDAQ:DYN - Free Report) during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 99,328 shares of the company's stock, valued at approximately $2March 30, 2025 | marketbeat.comDyne Therapeutics (NASDAQ:DYN) Trading 5.4% Higher - What's Next?Dyne Therapeutics (NASDAQ:DYN) Trading 5.4% Higher - Should You Buy?March 28, 2025 | marketbeat.comDyne Therapeutics (NASDAQ:DYN) Reaches New 12-Month Low - Here's What HappenedDyne Therapeutics (NASDAQ:DYN) Sets New 1-Year Low - Should You Sell?March 27, 2025 | marketbeat.comDyne Therapeutics (NASDAQ:DYN) Stock Price Down 4.2% - Should You Sell?Dyne Therapeutics (NASDAQ:DYN) Shares Down 4.2% - Should You Sell?March 26, 2025 | marketbeat.comDyne Therapeutics Appoints Erick J. Lucera as Chief Financial Officer to Support Late-Stage Clinical ProgramsMarch 22, 2025 | nasdaq.comDyne Therapeutics (NASDAQ:DYN) Given New $17.00 Price Target at JPMorgan Chase & Co.JPMorgan Chase & Co. decreased their price objective on Dyne Therapeutics from $18.00 to $17.00 and set a "neutral" rating for the company in a research note on Friday.March 22, 2025 | marketbeat.comDyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Chief Financial OfficerMarch 20, 2025 | globenewswire.comDyne Therapeutics Announces Appointment of Erick J. Lucera as Chief Financial OfficerMarch 20, 2025 | globenewswire.comDyne Therapeutics (NASDAQ:DYN) Trading Up 3.8% - What's Next?Dyne Therapeutics (NASDAQ:DYN) Shares Up 3.8% - Still a Buy?March 19, 2025 | marketbeat.comVictory Capital Management Inc. Has $1.45 Million Stake in Dyne Therapeutics, Inc. (NASDAQ:DYN)Victory Capital Management Inc. lifted its holdings in shares of Dyne Therapeutics, Inc. (NASDAQ:DYN - Free Report) by 100.9% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 61,348 shares of the company's sMarch 19, 2025 | marketbeat.comDyne Therapeutics (NASDAQ:DYN) Earns "Buy" Rating from HC WainwrightHC Wainwright restated a "buy" rating and set a $46.00 price target on shares of Dyne Therapeutics in a research note on Monday.March 18, 2025 | marketbeat.comDyne Therapeutics (NASDAQ:DYN) Shares Gap Up - Here's What HappenedDyne Therapeutics (NASDAQ:DYN) Shares Gap Up - Here's WhyMarch 18, 2025 | marketbeat.comChardan Capital Reiterates "Buy" Rating for Dyne Therapeutics (NASDAQ:DYN)Chardan Capital reiterated a "buy" rating and set a $50.00 price target on shares of Dyne Therapeutics in a research note on Monday.March 18, 2025 | marketbeat.comSkandinaviska Enskilda Banken AB publ Makes New Investment in Dyne Therapeutics, Inc. (NASDAQ:DYN)Skandinaviska Enskilda Banken AB publ bought a new position in shares of Dyne Therapeutics, Inc. (NASDAQ:DYN - Free Report) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 26,816 shares ofMarch 18, 2025 | marketbeat.comDyne’s DMD trial advances patient mobility and dystrophin expressionMarch 17, 2025 | finance.yahoo.comStifel Nicolaus Sticks to Its Buy Rating for Dyne Therapeutics (DYN)March 17, 2025 | markets.businessinsider.comDyne Therapeutics (DYN) Gets a Buy from ScotiabankMarch 17, 2025 | markets.businessinsider.comDyne reports new long-term data from Phase 1/2 DELIVER trial of DYNE-251March 17, 2025 | msn.comDyne announces new long-term data from Phase 1/2 DELIVER trial of DYNE-251March 16, 2025 | markets.businessinsider.comDyne Therapeutics Announces New Long-Term Clinical Data from Phase 1/2 DELIVER Trial of DYNE-251 in Duchenne Muscular Dystrophy Demonstrating Unprecedented and Sustained Functional Improvement Through 18 MonthsMarch 16, 2025 | globenewswire.comDyne Therapeutics, Inc. (NASDAQ:DYN) Given Average Rating of "Buy" by BrokeragesDyne Therapeutics, Inc. (NASDAQ:DYN - Get Free Report) has been assigned an average recommendation of "Buy" from the fifteen ratings firms that are currently covering the company, Marketbeat reports. One equities research analyst has rated the stock with a hold recommendation, twelve have issuedMarch 15, 2025 | marketbeat.comDyne Therapeutics, Inc. (NASDAQ:DYN) SVP Richard William Scalzo Sells 1,343 SharesDyne Therapeutics, Inc. (NASDAQ:DYN - Get Free Report) SVP Richard William Scalzo sold 1,343 shares of the stock in a transaction dated Tuesday, March 11th. The stock was sold at an average price of $11.38, for a total value of $15,283.34. Following the completion of the sale, the senior vice president now owns 122,330 shares of the company's stock, valued at $1,392,115.40. This trade represents a 1.09 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.March 14, 2025 | marketbeat.comDyne Therapeutics, Inc. (NASDAQ:DYN) Insider Oxana Beskrovnaya Sells 2,153 SharesDyne Therapeutics, Inc. (NASDAQ:DYN - Get Free Report) insider Oxana Beskrovnaya sold 2,153 shares of Dyne Therapeutics stock in a transaction that occurred on Tuesday, March 11th. The stock was sold at an average price of $11.38, for a total transaction of $24,501.14. Following the completion of the transaction, the insider now directly owns 195,840 shares in the company, valued at approximately $2,228,659.20. This trade represents a 1.09 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.March 14, 2025 | marketbeat.comRichard William Scalzo Sells 1,343 Shares of Dyne Therapeutics, Inc. (NASDAQ:DYN) StockMarch 14, 2025 | insidertrades.comDyne: Accelerated Approval Of DYNE-101 Might Be Possible With Surrogate BiomarkerMarch 13, 2025 | seekingalpha.comDyne Therapeutics (NASDAQ:DYN) Coverage Initiated by Analysts at BMO Capital MarketsBMO Capital Markets began coverage on shares of Dyne Therapeutics in a research report on Wednesday. They set an "outperform" rating and a $50.00 price objective for the company.March 13, 2025 | marketbeat.comDyne wins new Outperform at BMO on prospects for lead drugMarch 12, 2025 | msn.comBMO Capital Initiates Coverage of Dyne Therapeutics (DYN) with Outperform RecommendationMarch 12, 2025 | msn.comDyne Therapeutics initiated with an Outperform at BMO CapitalMarch 11, 2025 | markets.businessinsider.comDyne Therapeutics to Present at Stifel 2025 Virtual CNS ForumMarch 11, 2025 | globenewswire.comDyne Therapeutics (NASDAQ:DYN) Sets New 12-Month Low - Here's What HappenedDyne Therapeutics (NASDAQ:DYN) Sets New 12-Month Low - What's Next?March 11, 2025 | marketbeat.comScotiabank Initiates Coverage of Dyne Therapeutics (DYN) with Sector Outperform RecommendationMarch 8, 2025 | msn.comDyne Therapeutics (NASDAQ:DYN) Now Covered by Analysts at ScotiabankScotiabank began coverage on Dyne Therapeutics in a research report on Friday. They set a "sector outperform" rating and a $50.00 target price on the stock.March 8, 2025 | marketbeat.comLisanti Capital Growth LLC Raises Position in Dyne Therapeutics, Inc. (NASDAQ:DYN)Lisanti Capital Growth LLC raised its position in Dyne Therapeutics, Inc. (NASDAQ:DYN - Free Report) by 233.7% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 57,755 shares of the company's stock after acquiring an adMarch 8, 2025 | marketbeat.comDyne Therapeutics initiated with an Outperform at ScotiabankMarch 7, 2025 | markets.businessinsider.comItalian drugmaker with new Duchenne drug opens U.S. HQ in Mass.March 7, 2025 | bizjournals.comDyne Therapeutics (NASDAQ:DYN) Hits New 12-Month Low - Time to Sell?Dyne Therapeutics (NASDAQ:DYN) Hits New 12-Month Low - What's Next?March 6, 2025 | marketbeat.comDyne Therapeutics (NASDAQ:DYN) Stock Price Down 6.4% on Analyst DowngradeDyne Therapeutics (NASDAQ:DYN) Shares Down 6.4% on Analyst DowngradeMarch 3, 2025 | marketbeat.comWhat is HC Wainwright's Estimate for DYN Q1 Earnings?Dyne Therapeutics, Inc. (NASDAQ:DYN - Free Report) - Investment analysts at HC Wainwright issued their Q1 2025 earnings per share estimates for shares of Dyne Therapeutics in a research report issued to clients and investors on Friday, February 28th. HC Wainwright analyst A. Fein anticipates thatMarch 3, 2025 | marketbeat.comDyne Therapeutics (DYN) Gets a Buy from Stifel NicolausMarch 1, 2025 | markets.businessinsider.comDyne Therapeutics (NASDAQ:DYN) Receives "Buy" Rating from Chardan CapitalChardan Capital restated a "buy" rating and set a $50.00 price objective on shares of Dyne Therapeutics in a research note on Friday.March 1, 2025 | marketbeat.comPiper Sandler Cuts Dyne Therapeutics (NASDAQ:DYN) Price Target to $48.00Piper Sandler dropped their target price on shares of Dyne Therapeutics from $53.00 to $48.00 and set an "overweight" rating for the company in a research report on Friday.March 1, 2025 | marketbeat.comHC Wainwright Lowers Dyne Therapeutics (NASDAQ:DYN) Price Target to $46.00HC Wainwright reduced their target price on Dyne Therapeutics from $55.00 to $46.00 and set a "buy" rating for the company in a research note on Friday.March 1, 2025 | marketbeat.comDyne Therapeutics (NASDAQ:DYN) Releases Quarterly Earnings Results, Beats Estimates By $0.04 EPSDyne Therapeutics (NASDAQ:DYN - Get Free Report) announced its earnings results on Thursday. The company reported ($0.88) EPS for the quarter, beating the consensus estimate of ($0.92) by $0.04.February 28, 2025 | marketbeat.com Remove Ads Get Dyne Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for DYN and its competitors with MarketBeat's FREE daily newsletter. Email Address DYN Media Mentions By Week DYN Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. DYN News Sentiment▼0.390.61▲Average Medical News Sentiment DYN News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. DYN Articles This Week▼76▲DYN Articles Average Week Remove Ads Get Dyne Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for DYN and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies ADMA Biologics News Today PTC Therapeutics News Today Zai Lab News Today Organon & Co. News Today Arcellx News Today Avidity Biosciences News Today Ultragenyx Pharmaceutical News Today Rhythm Pharmaceuticals News Today SpringWorks Therapeutics News Today Akero Therapeutics News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:DYN) was last updated on 4/4/2025 by MarketBeat.com Staff From Our PartnersWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredFeds Just Admitted It—They Can Take Your CashThe Government Just Said Your Money Isn't Yours That's right—According to the DOJ, YOUR hard-earned money i...Priority Gold | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredThree new patents reveal Elon and Trump’s secret “Project America”Right now for a limited time… You can get Tim Bohen’s top 5 Trump stocks for 2025… For only ONE DOLLAR!...Timothy Sykes | SponsoredTrump’s Secret WeaponPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredTrump Makes Major Crypto AnnouncementTrump Ends the “War on Crypto” I expect it to pump the market, which is why I'm recommending ONE coin to al...Crypto 101 Media | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Dyne Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Dyne Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
